Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...

Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin ...

Oruka Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 61.79%. As a group, “Diagnostic substances” companies have a potential upside of 41.98%.

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...

The immune disease drug developer expects to raise $300 million in a private financing set to close before its combination ...

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin ...

Traders use this information to analyze potential trades and assess market sentiment for Oruka Therapeutics. In The Money Expiration Date December 20, 2024 March 21, 2025 ...

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases ...